Director at Serina Therapeutics (SER) makes open-market buy of 12,183 shares

Rhea-AI Filing Summary

Serina Therapeutics director Marshall Richard Peter bought 12,183 shares of common stock in an open-market transaction. The purchase occurred on May 19, 2026 at a weighted average price of $1.65 per share, with trade prices ranging from $1.59 to $1.73. Following this transaction, he directly holds 12,183 shares of Serina Therapeutics common stock.

Insider Trade Summary

Net Buyer: 12,183 shares ($20,102)

Net Buy 1 txn

Insider Marshall Richard Peter

Role null

Bought 12,183 shs ($20K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	12,183	$1.65	$20K

Holdings After Transaction: Common Stock — 12,183 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 12,183 shares Weighted average price: $1.65 per share Price range: $1.59–$1.73 per share +1 more

4 metrics

Shares purchased 12,183 shares Open-market purchase on May 19, 2026

Weighted average price $1.65 per share Average of multiple trades on May 19, 2026

Price range $1.59–$1.73 per share Range of individual trade prices in the purchase

Shares owned after 12,183 shares Direct holdings following the reported transaction

Key Terms

open-market purchase, weighted average purchase price, Common Stock, Form 4

4 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average purchase price financial

"The price reflects the weighted average purchase price of multiple transactions"

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marshall Richard Peter

(Last) (First) (Middle)

601 GENOME WAY, SUITE 2001

(Street)

HUNTSVILLE ALABAMA 35806

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		P		12,183	A	$1.65(1)	12,183	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.59 per share to a high purchase price of $1.73 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price.

Remarks:

	/s/ Marshall Richard Peter	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Serina Therapeutics (SER) report?

Serina Therapeutics reported that director Marshall Richard Peter bought 12,183 shares of common stock. The open-market purchase was made at a weighted average price of $1.65 per share, indicating a direct increase in his personal holdings of Serina’s stock.

How many Serina Therapeutics (SER) shares did the director buy and at what price?

Director Marshall Richard Peter acquired 12,183 Serina Therapeutics common shares. He paid a weighted average price of $1.65 per share, based on multiple trades with prices ranging from $1.59 to $1.73 per share on the transaction date.

When did the Serina Therapeutics (SER) insider purchase take place?

The insider purchase took place on May 19, 2026. On that date, director Marshall Richard Peter executed multiple open-market trades in Serina Therapeutics common stock, which together resulted in a weighted average purchase price of $1.65 per share.

What are Marshall Richard Peter’s Serina Therapeutics (SER) holdings after the trade?

After the reported transaction, Marshall Richard Peter directly owns 12,183 shares of Serina Therapeutics common stock. This post-transaction figure matches the total number of shares purchased in the filing, indicating his full reported stake in this Form 4.

Was the Serina Therapeutics (SER) insider trade a market purchase or another type?

The transaction was an open-market purchase of common stock. The Form 4 identifies it with code “P,” meaning a purchase in the open market or private transaction, and classifies the shares as directly owned by the reporting director after the trade.